Equity · Healthcare
EBS
NYSEEmergent BioSolutions (EBS)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for EBS to draw a line in its place.
- Market cap
- 303.3M USD
- Revenue, year to Dec 2025
- 742.9M USD
- EPS, diluted, year to Dec 2025
- 0.93 USD
- 52-week range
- 4.45 USD – 13.92 USD
- Avg volume
- 72.7K
as of Nov 4, 2026
Have Emergent BioSolutions (EBS) insiders bought or sold shares recently?
EBS has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 7 October 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 07 Oct 2026 | DeGolyer Donald WDirector | Sell | 17,800 | 126K USD |
| 01 Oct 2026 | Williams Paul AnthonySVP, Products Business | Sell | 3,000 | 20K USD |
| 01 Jul 2026 | Williams Paul AnthonySVP, Products Business | Sell | 3,000 | 25K USD |
| 01 May 2026 | Dayal Sujata TyagiDirector | Sell | 13,761 | 116K USD |
| 01 May 2026 | DeGolyer Donald WDirector | Sell | 15,481 | 130K USD |
| 01 May 2026 | Zoon Kathryn CDirector | Sell | 17,202 | 144K USD |
| 30 Apr 2026 | Katkin KeithDirector | Sell | 15,481 | 128K USD |
| 01 Apr 2026 | Williams Paul AnthonySVP, Products Business | Sell | 4,000 | 34K USD |
| 05 Dec 2025 | Richard Ronald | Sell | 21,984 | 263K USD |
| 10 Nov 2025 | DeGolyer Donald W | Sell | 17,801 | 188K USD |
| 07 Nov 2025 | Dayal Sujata Tyagi | Sell | 8,552 | 86K USD |
| 07 Oct 2025 | Glessner ColeenEVP, Quality & Ethics, and CPL | Sell | 30,608 | 306K USD |
| Sold | 12 open-market sales | 168,670 | $1.57M |
45 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Jun 2026 | LINDAHL RICHARD SEVP, Chief Financial Officer | Tax withheld | 3,964 | 32K USD |
| 08 Jun 2026 | Glessner ColeenEVP, Quality & Ethics, and CPL | Tax withheld | 2,018 | 16K USD |
| 08 Jun 2026 | Williams Paul AnthonySVP, Products Business | Tax withheld | 694 | 6K USD |
| 08 Jun 2026 | Hartzel WilliamSVP, Bioservices | Tax withheld | 1,741 | 14K USD |
| 30 Apr 2026 | Dayal Sujata TyagiDirector | Award | 25,344 | |
| 30 Apr 2026 | DeGolyer Donald WDirector | Award | 25,344 | |
| 30 Apr 2026 | FOWLER JOHN D JRDirector | Award | 25,344 | |
| 30 Apr 2026 | Katkin KeithDirector | Award | 25,344 | |
| 30 Apr 2026 | Richard RonaldDirector | Award | 25,344 | |
| 30 Apr 2026 | Harsanyi ZsoltChairman | Award | 25,344 | |
| 30 Apr 2026 | White Marvin LDirector | Award | 25,344 | |
| 30 Apr 2026 | Fowler Neal FranklinDirector | Award | 25,344 |
Showing the 12 most recent of 45 compensation filings in this window. The figures above count all of them.
Which funds hold Emergent BioSolutions (EBS)?
6 of the 45 institutional funds we track reported a Emergent BioSolutions position for the quarter ended 30 Jun 2026 — a combined 35.6M USD; the latest of those filings landed 14 Aug 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 1,072,185 | 9.0M USD | +101.5% |
| AQR Capital Management | Held (±25%) | 1,041,151 | 8.7M USD | +5.2% |
| D. E. Shaw & Co. | Held (±25%) | 900,108 | 7.5M USD | −10.3% |
| Renaissance Technologies | Held (±25%) | 683,247 | 5.7M USD | +4.1% |
| Two Sigma Investments | Held (±25%) | 488,284 | 4.1M USD | −15.4% |
| Man Group | Added | 66,527 | 557K USD | +47.2% |
| Marshall Wace | Exited |
Have members of Congress traded Emergent BioSolutions (EBS)?
The most recent congressional trade disclosed in Emergent BioSolutions is a sale by Steve Cohen (house, TN), dated 11 Dec 2024.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 11 Dec 2024 | Steve Cohenhouse · Democrat–TN | Sale | 1K USD–15K USD | 30 days |
What has been filed or recorded for Emergent BioSolutions (EBS)?
The filings we hold for Emergent BioSolutions, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.64 USD | |
| 30 Sep 2026 | Financials | Total assets | 995.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 313.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −3.49 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.07 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.93 USD | Revenue $743M |
| 31 Dec 2025 | Financials | Revenue | 742.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 52.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.93 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.91 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.22 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 1.19 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.60 USD | Revenue $1.04B |
Emergent BioSolutions (EBS): frequently asked questions
What is Emergent BioSolutions’ market cap?
Emergent BioSolutions is worth 303.3M USD by market value as of 4 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Emergent BioSolutions’ revenue?
Emergent BioSolutions reported revenue of 742.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Emergent BioSolutions insiders bought or sold shares recently?
No Emergent BioSolutions insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 7 Oct 2026 (SEC Form 4). See Insiders
Which funds own Emergent BioSolutions?
6 of the 45 funds we track reported a Emergent BioSolutions position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, AQR Capital Management and D. E. Shaw & Co. See Funds
Have members of Congress traded Emergent BioSolutions?
Yes. 1 trade in Emergent BioSolutions appears in the congressional disclosures we hold: a sale by Steve Cohen (House, TN) dated 11 Dec 2024, filed 10 Jan 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Emergent BioSolutions last report earnings?
Emergent BioSolutions last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.64 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings